Symbols

CTOR

Citius Oncology·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CTOR

Citius Oncology, Inc.

New targeted tumor therapy development company

Industry

Life Science Tools and Services

Established Date

03/01/2021

Listing Date

12/08/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

09-30

Website

www.citiusonc.com

Security Type

Common stock

Office address

11 Commerce Drive, First Floor, Cranford, NJ 07016

Business

Introduction

Citius Oncology, Inc. (formerly TenX Keane Acquisition) was incorporated in the Cayman Islands on March 1, 2021, and was relocated and naturalized as a Delaware company on August 5, 2024. Citius Oncology will serve as a platform to develop and commercialize novel targeted tumor therapies. In August 2024, its main asset, LYMPHIR, received FDA approval for the treatment of adult patients with relapsed or refractory CTCL who have received at least one systemic treatment.

Company Financials

EPS

CTOR has released its 2026 Q1 earnings. EPS was reported at -0.06, versus the expected -0.04, missing expectations. The chart below visualizes how CTOR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CTOR has released its 2026 Q1 earnings report, with revenue of 3.94M, reflecting a YoY change of NaN%, and net profit of -5.53M, showing a YoY change of 16.90%. The Sankey diagram below clearly presents CTOR's revenue sources and cost distribution.